Brokerages expect Unum Therapeutics Inc (NASDAQ:UMRX) to report $3.15 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Unum Therapeutics’ earnings, with the lowest sales estimate coming in at $1.80 million and the highest estimate coming in at $4.41 million. Unum Therapeutics reported sales of $2.22 million during the same quarter last year, which would suggest a positive year over year growth rate of 41.9%. The business is scheduled to issue its next quarterly earnings report on Monday, May 13th.

On average, analysts expect that Unum Therapeutics will report full year sales of $13.96 million for the current fiscal year, with estimates ranging from $7.00 million to $17.62 million. For the next financial year, analysts anticipate that the business will post sales of $17.10 million, with estimates ranging from $9.00 million to $25.33 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. The company had revenue of $3.80 million during the quarter, compared to analysts’ expectations of $2.58 million. Unum Therapeutics had a negative return on equity of 96.46% and a negative net margin of 354.88%.

Several research analysts recently weighed in on UMRX shares. Cowen started coverage on Unum Therapeutics in a research report on Tuesday, February 26th. They set a “market perform” rating for the company. Zacks Investment Research cut Unum Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 21st. SunTrust Banks lowered their price objective on Unum Therapeutics to $10.00 and set a “buy” rating for the company in a research report on Friday, March 29th. They noted that the move was a valuation call. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Unum Therapeutics in a research report on Friday, March 29th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $14.60.

In related news, insider Seth Ettenberg sold 11,485 shares of the company’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $4.12, for a total value of $47,318.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its stake in Unum Therapeutics by 2,782.4% in the third quarter. JPMorgan Chase & Co. now owns 20,753 shares of the company’s stock valued at $213,000 after buying an additional 20,033 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Unum Therapeutics in the third quarter valued at about $235,000. Renaissance Technologies LLC purchased a new stake in Unum Therapeutics in the third quarter valued at about $723,000. Jane Street Group LLC purchased a new stake in Unum Therapeutics in the third quarter valued at about $150,000. Finally, Vanguard Group Inc. raised its stake in Unum Therapeutics by 4.2% in the third quarter. Vanguard Group Inc. now owns 552,380 shares of the company’s stock valued at $5,690,000 after buying an additional 22,510 shares during the last quarter. 47.46% of the stock is owned by hedge funds and other institutional investors.

UMRX stock traded up $0.04 during trading on Thursday, hitting $3.60. 63,569 shares of the company traded hands, compared to its average volume of 86,913. Unum Therapeutics has a 1 year low of $3.30 and a 1 year high of $17.66.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

See Also: What is a Reverse Stock Split?

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.